Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures
- PMID: 11206218
- DOI: 10.1007/s10434-001-0013-9
Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures
Abstract
Background: The hypothesis that sentinel lymph node (SLN) mapping in breast cancer patients is optimized by combining blue dye and isotope is reasonable and intuitive. Despite this, few studies examine in detail the factors contributing to the success of these techniques, either individually or in combination.
Methods: During a time period of 21/2 years, 1000 consecutive patients at Memorial Sloan-Kettering Cancer Center had SLN mapping performed by using both blue dye and isotope, with preoperative lymphoscintigraphy (LSG). Among the 966 patients with invasive cancer, 12 variables were examined for their correlation with the success of SLN localization by blue dye, by isotope, and by the combined method, using univariate and multivariate models.
Results: By univariate analysis, blue dye success was more frequent in association with: a positive LSG (P = .02), age < or = 60 (P < .0005), a previous surgical biopsy (P = .03), and an outer quadrant tumor (P < .0005). Isotope success was more frequent with a positive LSG (P < .0005), age < or = 60 (P = .004), and intradermal isotope injection (P < .0005). Combined (dye and/or isotope) success was more frequent when there was a positive LSG (P < .0005), age < or = 60 (P = .006) and intradermal isotope injection (P < .0005). In multivariate analysis, blue dye success remained uniquely associated with outer quadrant tumor location (P < .0005), and isotope success was uniquely associated with intradermal isotope injection (P = .012). Combined success was more frequent with a positive LSG (P < .0005), age < or = 60 (P = .033), and intradermal isotope injection (P = .003).
Conclusions: The five variables associated with successful SLN localization by blue dye or by isotope overlap but are not identical. Only three of these, intradermal isotope injection, a positive LSG, and age < 60, predicted success by the dye-isotope combination in the multivariate model. Dye and isotope complement each other, and SLN biopsy for breast cancer should use both.
Comment in
-
Modification of the sentinel node technique: it was a hit in New York, but will it play in Poughkeepsie?Ann Surg Oncol. 2001 Jan-Feb;8(1):3-6. doi: 10.1007/s10434-001-0003-y. Ann Surg Oncol. 2001. PMID: 11206221 No abstract available.
Similar articles
-
A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer.J Am Coll Surg. 2001 Nov;193(5):473-8. doi: 10.1016/s1072-7515(01)01038-9. J Am Coll Surg. 2001. PMID: 11708502
-
Intradermal radiocolloid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients.Ann Surg Oncol. 1999 Jul-Aug;6(5):450-4. doi: 10.1007/s10434-999-0450-4. Ann Surg Oncol. 1999. PMID: 10458682 Clinical Trial.
-
Concordance and validation study of sentinel lymph node biopsy for breast cancer using subareolar injection of blue dye and technetium 99m sulfur colloid.J Am Coll Surg. 2002 Oct;195(4):467-75. doi: 10.1016/s1072-7515(02)01312-1. J Am Coll Surg. 2002. PMID: 12375751
-
Intradermal radioisotope is superior to peritumoral blue dye or radioisotope in identifying breast cancer sentinel nodes.J Am Coll Surg. 2004 Oct;199(4):561-6. doi: 10.1016/j.jamcollsurg.2004.06.018. J Am Coll Surg. 2004. PMID: 15454139 Review.
-
The application of sentinel node radiolocalization to solid tumors of the head and neck: a 10-year experience.Laryngoscope. 2004 Jan;114(1):2-19. doi: 10.1097/00005537-200401000-00002. Laryngoscope. 2004. PMID: 14709988 Review.
Cited by
-
Current management of the axilla in patients with clinically node-negative breast cancer: a nationwide survey of United Kingdom breast surgeons.Int Semin Surg Oncol. 2007 Feb 14;4:4. doi: 10.1186/1477-7800-4-4. Int Semin Surg Oncol. 2007. PMID: 17300717 Free PMC article.
-
Comparison of the indocyanine green dye method versus the combined method of indigo carmine blue dye with indocyanine green fluorescence imaging for sentinel lymph node biopsy in breast conservative therapy for stage ≤IIA breast cancer.BMC Womens Health. 2018 Sep 18;18(1):151. doi: 10.1186/s12905-018-0646-5. BMC Womens Health. 2018. PMID: 30227837 Free PMC article.
-
Metasin-an intra-operative RT-qPCR assay to detect metastatic breast cancer in sentinel lymph nodes.Int J Mol Sci. 2013 Jun 24;14(7):12931-52. doi: 10.3390/ijms140712931. Int J Mol Sci. 2013. PMID: 23797656 Free PMC article.
-
ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes in Breast Cancer: Results of a Prospective Open-label Clinical Trial.Geburtshilfe Frauenheilkd. 2015 Sep;75(9):935-940. doi: 10.1055/s-0035-1557905. Geburtshilfe Frauenheilkd. 2015. PMID: 26500370 Free PMC article.
-
Novel Dual Tracer Indocyanine Green and Radioisotope Versus Gold Standard Sentinel Lymph Node Biopsy in Breast Cancer: The GREENORBLUE Trial.Ann Surg Oncol. 2023 Oct;30(11):6520-6527. doi: 10.1245/s10434-023-13824-6. Epub 2023 Jul 4. Ann Surg Oncol. 2023. PMID: 37402976 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical